Loading
A phase 2 trial of Progestins in Endometrial cancer, run by Chang Gung Memorial Hospital, with a status the registry has not verified recently.
Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer is a phase 2 interventional study registered as NCT02990728 by Chang Gung Memorial Hospital, with 120 participants planned, started 2016-03 and due to reach its primary completion in 2018-03. Interventions recorded: Metformin, Mirena®. Conditions recorded: Endometrial Cancer.
Linked to the drug Progestins because the registry names it among its interventions and Endometrial cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD), Endometrial cancer and the tag pipeline.
Shares Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD), Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/